Doorgaan naar hoofdcontent

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms, Date of authorisation: 11/02/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms, Date of authorisation: 11/02/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Carcinoma, Non-Small-Cell Lung;Thyroid Neoplasms, Date of authorisation: 11/02/2021, Revision: 7, Status: Authorised

Wil je het laatste nieuws in jouw mailbox? Meld je dan aan voor de nieuwsbrief